Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab

Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab

Nivolumab and ipilimumab (NIVO + IPI) is standard therapy for patients with advanced renal cell carcinoma (RCC). Absolute lymphocyte count (ALC) is a valuable prognostic factor in patients with various cancers treated with immune checkpoint inhibitors. Herein, we determined the prognostic value of p...

Full description

Bibliographic Details
Main Authors: Kosuke Ueda, Naoyuki Ogasawara, Naoki Ito, Satoshi Ohnishi, Hiroki Suekane, Hirofumi Kurose, Tasuku Hiroshige, Katsuaki Chikui, Keiichiro Uemura, Kiyoaki Nishihara, Makoto Nakiri, Shigetaka Suekane, Tsukasa Igawa
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Journal of Clinical Medicine
Subjects:
renal cell carcinoma
immune checkpoint inhibitor
nivolumab plus ipilimumab
lymphocyte count
Online Access:https://www.mdpi.com/2077-0383/12/6/2417

Internet

https://www.mdpi.com/2077-0383/12/6/2417

Similar Items